Recursion Pharmaceuticals Launches $300M At-The-Market Offering Amidst Financial Challenges and Positive Clinical Data

summarizeSummary

Recursion Pharmaceuticals has launched a $300 million At-The-Market (ATM) offering to sell Class A Common Stock, providing crucial capital for operations and program advancement, following its recent 10-K and positive Phase 2 data.

check_boxKey Events

• Launches $300 Million At-The-Market Offering

  The company has entered into a sales agreement with TD Cowen to offer and sell up to $300,000,000 of its Class A Common Stock through an At-The-Market (ATM) program. This prospectus supplement finalizes the terms of the ATM program announced in the concurrent 10-K filing.

• Significant Potential Dilution

  The offering could result in the sale of approximately 84.99 million shares, representing a potential dilution of about 16.3% based on the last reported sale price of $3.53 per share on February 24, 2026, and the company's outstanding shares as of December 31, 2025.

• Proceeds for General Corporate Purposes and Runway Extension

  Net proceeds from the offering are intended for general corporate purposes, including funding preclinical and clinical programs, platform technologies, digital chemistry, foundation model construction, and extending the company's financial runway.

• Context of Financial Challenges and Clinical Progress

  This capital raise follows the company's concurrent 10-K filing, which reported widening losses and unremediated material weaknesses in internal controls, but also comes alongside an 8-K announcing positive Phase 2 data for REC-4881, highlighting a critical need for funding to support ongoing development.

auto_awesomeAnalysis

Recursion Pharmaceuticals has launched an At-The-Market (ATM) offering to sell up to $300 million of its Class A Common Stock. This offering, detailed in this prospectus supplement, operationalizes the $300 million ATM program previously announced in the concurrent 10-K filing. The capital raise is substantial, representing approximately 16.3% of the company's current market capitalization, and is intended for general corporate purposes, including funding preclinical and clinical programs, platform technologies, and runway extension. While dilutive, this financing is critical for the company, especially given the concurrent 10-K filing reporting widening losses and unremediated material weaknesses in internal controls. The ability to secure this funding, even through a dilutive ATM, provides essential liquidity and supports ongoing operations and development, particularly following the positive Phase 2 clinical data for REC-4881 also announced today.